Results 171 to 180 of about 13,648,107 (360)

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. [PDF]

Br J Haematol, 2021
Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, Thieblemont C, Wermke M, Song KW, Avivi I, Kuruvilla J, Dührsen U, Zheng Y, Vardhanabhuti S, Dong J, Bot A, Rossi JM, Plaks V, Sherman M, Kim JJ, Kerber A, Kersten MJ.   +21 more
europepmc   +1 more source

Societal benefits of cyanobacteria harmful algal bloom management in Lake Okeechobee in Florida—Potential damages avoided during the 2018 event under U.S. Army Corps of Engineers Harmful Algal Bloom Interception, Treatment, and Transformation System scenarios [PDF]

Inoussa Boubacar, Emily J. Pindilli, Eleanor D. Brown, Benjamin Simon, Kristin Skrabis, Ian Luby   +5 more
openalex   +1 more source

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

FEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan, Bethany C. Guerra, Selina Uranga, Jessica M. Cardin, Steven E. Riechman, Mariana Janini Gomes, James D. Fluckey   +6 more
wiley   +1 more source

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. [PDF]

Eur J Cancer, 2022
Roubaud G, Özgüroğlu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K.   +22 more
europepmc   +1 more source

Navigating new norms: a systematic review of factors for the development of effective digital tools in higher education

FEBS Open Bio, EarlyView.
What factors make for an effective digital learning tool in Higher Education? This systematic review identifies elements of a digital tool that published examples reveal to be features of an engaging and impactful digital tool. A systematic literature search yielded 25 research papers for analysis.
Akmal Arzeman, Jessica Haines, Connie Pritchard, Stephen Rutherford, Nigel Francis   +4 more
wiley   +1 more source

Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). [PDF]

BMJ Open, 2023
Osawa T, Fujii Y, Kimura G, Kitamura H, Nagashima Y, Iizumi S, Osaka T, Tsubouchi R, Shinohara N.   +8 more
europepmc   +1 more source

Towards wind machines park management automatization to improve fight against spring frost events

, 2021
Clara Le, Dominique Heitz, Johan Carlier, Hervé Quénol, Emmanuel Buisson   +4 more
openalex   +1 more source

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, EarlyView.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. [PDF]

J Mark Access Health Policy, 2022
Fan L, Zhang Y, Maguire P, Muston D, Monberg M, Earla JR, Mihai A, Gulati P.   +7 more
europepmc   +1 more source

Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention [PDF]

Stephanie Wuyts, J. de Moor, Kristin Jochmans, Pieter‐Jan Cortoos, Fenne Vandervorst, Stéphane Steurbaut, Alain Dupont, Pieter Cornu   +7 more
openalex   +1 more source